Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Disease Indication, By Route Of Administration, By Drug Class, By Distribution Channel, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Stomach Cancer Treatment market size is expected to hit around USD 15.2 billion by 2030 from valued at USD 4.83 billion in 2022 and growing at a CAGR of 14.9% from 2022 to 2030.

https://www.novaoneadvisor.com/reportimg/Stomach-Cancer-Treatment-Market-2022-to-2030.jpg

Key Takeaways:

  • The targeted therapy treatment type segment held the second-largest revenue share in 2021 due to the robust clinical pipeline and approval of new products. For instance, in January 2021, the U.S. FDA approved Enhertu for the treatment of patients with metastatic or locally advanced HER-2 positive gastric cancers
  • By treatment type, immunotherapy is anticipated to witness the fastest growth during the forecast period due to the launch and adoption of PD-1 inhibitors such as Opdivo and Keytruda in the gastric cancer therapy market
  • By disease indication, the gastric cancer/gastroesophageal junction cancer segment is expected to maintain its lead during the forecast period due to the high prevalence of the disease and the availability of various products. The gastrointestinal stromal tumors (GISTs) segment is expected to grow due to the increasing number of product launches
  • Based on the distribution channel, the specialty and retail pharmacies segment dominated the gastric cancer therapy market in 2021. Targeted and immunotherapy drugs often have special requirements in terms of storage and logistics and are therefore distributed by specialty pharmacies
  • Asia Pacific is expected to maintain its dominance during the forecast period due to the high disease burden and research initiatives in the region. According to a Globocan report, Asia accounts for around 75.3% of all new cases of gastric cancer in 2020
  • Europe is anticipated to witness considerable growth during the forecast period owing to the increasing target patient population and approval of targeted and immunotherapy drugs

Increasing uptake of immunotherapy and targeted therapy, coupled with the launch of new drugs, is expected to fuel growth.

According to Globocan, the incidence of gastric cancer in 2020 was around 1.1 million, which is expected to increase to 1.42 million by 2030. Increasing knowledge regarding the molecular basis of the disease has led to a rise in the number of targeted drugs and immunotherapy drugs being developed and launched in the market. HER-2 targeted drugs such as Herceptin have been available in the market since 2010. Another targeted drug, Cyramza, which is a VEGF-targeting monoclonal antibody, has been available since 2014. EGFR and PD-1 targeted drugs and immunotherapies are currently being developed for the treatment of gastric cancer.

The approval and subsequent launch of drugs in the clinical pipeline are also expected to drive the gastric cancer therapy market. For instance, in March 2021, the NMPA approved Eli Lilly and Innovent Biologics’ drug Sintilimab, a PD-1 inhibitor, for the treatment of gastric or gastroesophageal junction adenocarcinoma in China. Furthermore, in May 2020, the U.S. FDA granted the orphan drug designation to Enhertu for the treatment of gastric cancers. Subsequently, in January 2021, the U.S. FDA approved Enhertu for the treatment of advanced or metastatic forms of the disease.

Patent expiry of key drugs such as Herceptin and subsequent launch of biosimilars are expected to restrain the growth of the gastric cancer therapy market. Additionally, lesser adoption of targeted therapy due to high costs might hamper the growth of the market. For instance, Cyramza was not considered cost-effective as compared to other drugs. It was rejected by NICE due to a lack of cost-effectiveness in England. Furthermore, the product was rejected for reimbursement in France due to a lack of additional benefits compared to the clinically relevant comparators.

Report Scope of the Stomach Cancer Treatment Market

Report Coverage

Details

Market Size

USD 15.2 Billion by 2030

Growth Rate

CAGR of 14.9% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

Treatment type, disease indication, route of administration, drug class, distribution channel, and Region,

Companies Mentioned

Novartis AG; Pfizer, Inc.; Mylan N.V.; F. Hoffmann La Roche Ltd.; Eli Lilly and Company; Merck & Co., Inc.; Teva Pharmaceutical Industries Ltd.; Celltrion Healthcare Co., Ltd; Samsung Bioepis; Bristol Myers Squibb Company

 

Treatment Type Insights

The chemotherapy segment held the largest revenue share of the gastric cancer therapy market at over 41.0% in 2021 due to a high prescription rate. First-line therapy for patients diagnosed in early stages is generally surgery with adjuvant chemotherapy or neoadjuvant chemotherapy. An article suggests that around 65% of patients with advanced cancers, 85% with lymph node metastases, and 40% with metastatic disease undergo surgical procedures. Chemotherapy can be given either as neoadjuvant chemotherapy or adjuvant chemotherapy to shrink the tumor or kill the cancerous cells. Based on treatment type, the market is segmented into chemotherapy, immunotherapy, and targeted therapy.

The targeted therapy segment is expected to account for the largest share of the gastric cancer drugs market by the end of the forecast period, owing to product launches, recent advancements in the field of targeted therapy, and a robust clinical pipeline. On the other hand, the patent expiry of Herceptin is restraining the growth of this segment.

The immunotherapy segment is expected to witness the fastest growth during the forecast period due to increasing product launches. For instance, in March 2020, Bristol-Myers Squibb Company’s drug for Opdivo received approval for stomach cancer treatment in China. Another key immunotherapy drug approved is Keytruda. Immunotherapy in combination with chemotherapy is generally used as a third-line or fourth-line treatment option.

Route of Administration Insights

The injectable segment dominated the gastric cancer therapy market with a revenue share of over 91.0% in 2021. Most of the chemotherapy drugs, targeted drugs, and immunotherapy drugs are available in injectable form, leading to the dominance of this segment.

The oral segment is expected to expand at the highest rate during the forecast period. In order to overcome the cumbersome IV administration, many companies are developing oral chemotherapy agents for treatment. For instance, Ascelia Pharma is currently conducting Phase II clinical trials for the use of Oncoral (oral irinotecan) for the treatment of gastric cancer.

Drug Class Insights

The other drug classes segment accounted for the largest share of the gastric cancer drugs market of over 61.0% in 2021. Chemotherapy currently accounts for the largest share in this segment. Chemotherapy is still widely used as a first-line treatment in countries such as China and India, which have the highest prevalence of gastric cancer.

The PD-1/PD-L1 inhibitors segment is expected to expand at the fastest CAGR during the forecast period. The approval and increasing uptake of Keytruda and Opdivo for gastric cancer therapy are driving this segment. In addition to this, the NMPA approved TYVYT (sintilimab) for the treatment of gastric cancer in China in June 2021.

Distribution Channel Insights

The specialty and retail pharmacies segment dominated the gastric cancer therapy market in 2021 with a revenue share of over 66.0%. Most of the drugs used for the treatment of gastric cancer are distributed via specialty pharmacies as they have to be stored and distributed under specific conditions. For instance, in June 2021, Blueprint Medicines recently selected PANTHERx Rare Pharmacy and Biologics, by McKesson, for the distribution of its GIST treatment drug AYVAKIT. Based on the distribution channel, the market has been segmented into hospital pharmacies, specialty and retail pharmacies, and others.

The hospital pharmacies segment accounted for the second-largest share in 2021. Most patients with gastric cancer undergo inpatient administration of treatment in developing nations. This is one of the major factors fueling the growth of this segment.

Disease Indication Insights

The GC/GEJC segment held the largest revenue share of over 86.0% in 2021. The high disease burden coupled with a large number of approved products for this indication is contributing to the growth of this segment. According to Globocan, the 5-year prevalence of stomach cancer was around 1.8 million in 2020. Based on disease indication, the market is segmented into gastric cancer/gastroesophageal junction cancer (GC/GEJC) and gastrointestinal stromal tumors.

The gastrointestinal stromal tumors (GISTs) segment is estimated to witness moderate growth during the forecast period. GISTs are rare cancers and around 4,000 to 6,000 new cases are diagnosed every year in the U.S. Targeted drugs such as Ayvakit, Gleevec, Stivarga, and Qinlock are used for the treatment of GISTs.

Regional Insights

Asia Pacific dominated the gastric cancer therapy market in 2021 with a revenue share of over 56.0%. This is mainly due to the higher prevalence of gastric cancer in this region. For instance, in 2020, the number of new cases in Japan was around 138,000, and in China, it was around 479,000. In countries such as China, chemotherapy is still the most preferred treatment option; however, the presence of a strong product pipeline and the expected approval of the products will boost regional growth during the forecast period. For instance, in September 2021, AstraZeneca and Daiichi Sankyo Company dosed the first HER-2 positive gastric cancer patient in Phase II trials of Enhertuin China.

Europe is estimated to witness considerable growth during the forecast period due to increasing investments in the development of advanced treatment options and the rising target patient population. For instance, in October 2021, the European Commission approved Bristol Myers Squibb’s Opdivo for the treatment of gastrointestinal junction cancer.

Some of the prominent players in the Stomach Cancer Treatment Market include:

  • Novartis AG
  • Pfizer, Inc.
  • Mylan N.V.
  • F. Hoffmann La Roche Ltd.
  • Eli Lilly And Company
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Celltrion Healthcare Co., Ltd.
  • Samsung Bioepis
  • Bristol Myers Squibb Company

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Stomach Cancer Treatment market

  • Treatment Type
    • Immunotherapy
    • Targeted Therapy
    • Chemotherapy
    • Radiation Therapy And Surgery (Qualitative Analysis Only)
  • Disease Indication
    • Gastric Cancer/Gastroesophageal Junction Cancer
    • Gastrointestinal Stromal Tumors
  • Route of Administration
    • Oral
    • Injectable
  • Drug Class
    • PD-1/PD-L1 Inhibitors
    • HER2 Antagonists
    • VEGFR2 Antagonists
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Specialty & Retail Pharmacies
    • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Stomach Cancer Treatment industry analysis from 2022 to 2030 to identify the prevailing Stomach Cancer Treatment industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Stomach Cancer Treatment industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global Stomach Cancer Treatment industry trends, key players, market segments, application areas, and market growth strategies.

Report Detail

  • Report Code:7536
  • No. of Pages:150+
  • Format:PDF/PPT/Excel

Proceed To Buy

USD 3500
USD 7000